Echo IQ Expands Mayo Clinic Deal Ahead of FDA Nod for EchoSolv HF

• Expanded agreement with Mayo Clinic for EchoSolv HF distribution post-FDA clearance
• Improved commercial terms and automatic six-year contract extension
• EchoSolv HF demonstrated 99.5% sensitivity and 91.1% specificity in Mayo Clinic validation study
• Deployment planned via Mayo Clinic Platform, accessing 80+ partner hospitals